Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDULOX trial of duloxetine and patient education for multiorgan bodily distress syndrome
2022-002780-30Phase 4Active
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of duloxetine and benztropine in bodily distress syndrome (BDS), Functional Somatic Disorder (FSD) and somatic symptom disorder (SSD) (4 arms), sponsored by Aarhus University Hospital. Started Oct 2022; status: active.
02
Drugs
duloxetinebenztropine
03
Conditions
bodily distress syndrome (BDS)Functional Somatic Disorder (FSD)somatic symptom disorder (SSD)
Beyond the preview
Go deeper on 2022-002780-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002780-30.